Skip to main content

News Archive

News Archive - Debra Kain

New Chair Named for UC San Diego Department of Medicine

January 5, 2012

Wolfgang H. Dillmann, MD, has been selected as chair of the Department of Medicine at the University of California, San Diego School of Medicine. He has also been named the Helen M. Ranney Endowed Chair, the school's first faculty-funded endowed chair, founded in 1991 in honor of the department’s second chair.

UC San Diego’s William C. Mobley Recognized for Contributions to Down Syndrome

January 4, 2012

William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine and Chairman of the U.S. Scientific Advisory Committee of the Jérôme Lejeune Foundation, was recognized by U.S. Congressman Pete Sessions from the floor of the House of Representatives in December.

New Approach to Management of Overeating in Children

December 7, 2011

Overeating, whether in children or adults, often takes place even in the absence of hunger, resulting in weight gain and obesity. Current methods to treat such overeating in youth focus on therapies that restrict what kids may eat, requiring them to track their food intake and engage in intensive exercise.

A Rich, Collaborative Environment Advances Patient Care

November 29, 2011

UC San Diego Health Sciences has entered a period of remarkable growth, one that will strengthen its position as a destination academic medical center. In addition to the recent addition of the Sulpizio Cardiovascular Center and Medical Education & Telemedicine Building, plans are underway for the Altman Clinical and Translational Research Institute building (projected to open in 2015) and the Jacobs Medical Center (with a planned 2016 opening.)

Testing Antioxidant Drugs is Transparent

November 21, 2011

A study using genetically modified zebrafish to visualize early events involved in development of human atherosclerosis describes an efficient model – one that the researchers say offers many applications for testing the potential effectiveness of new antioxidant and dietary therapies.

Kawasaki Disease Linked to Wind Currents

November 10, 2011

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. In fact, if not diagnosed or treated in time, it can lead to irreversible heart damage. After 50 years of research, including genetic studies, scientists have been unable to pinpoint the cause of the disease.

Autism Linked with Excess of Neurons in Prefrontal Cortex

November 8, 2011

A study by researchers at the University of California, San Diego Autism Center of Excellence shows that brain overgrowth in boys with autism involves an abnormal, excess number of neurons in areas of the brain associated with social, communication and cognitive development.

Genetically Influenced Responses to Alcohol Affect Brain Activation

October 17, 2011

A study by researchers at the University of California, San Diego School of Medicine suggests that differences in brain activation in individuals with a low level of response to alcohol may contribute to their inability to recognize modest levels of alcohol intoxication. Their findings could provide the potential to identify individuals who are at risk for developing an alcohol-use disorder before it develops – in essence, providing a marker for this vulnerability.

UC San Diego School of Medicine Launches Hepatitis C Clinical Trials

October 13, 2011

A collaborative partnership between the UC San Diego Liver Center and Antiviral Research Center (AVRC) has resulted in 19 clinical trials for hepatitis C virus (HCV), focused on developing more effective and well-tolerated HCV treatments.

Progression of Lung Fibrosis Blocked in Mouse Model

October 5, 2011

A study by researchers at the University of California, San Diego School of Medicine may lead to a way to prevent the progression, or induce the regression, of lung injury that results from use of the anti-cancer chemotherapy drug Bleomycin. Pulmonary fibrosis caused by this drug, as well as Idiopathic Pulmonary Fibrosis (IPF) from unknown causes, affect nearly five million people worldwide. No therapy is known to improve the health or survival of patients.
Category navigation with Social links